Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference
Clinical-Stage Biotech to Unveil Off-the-Shelf Non-Gene Modified Hematopoietic Stem Cells and Its Derived Immune Cell Therapies
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) — Cell BioEngines, Inc., a biotechnology company focused on the development of ‘off-the-shelf’ ‘non-gene modified’ hematopoietic stem cells and its derived immune cell therapies for cancer patients, today announced that Dr. Ajay Vishwakarma, Founder and CEO of Cell BioEngines, will be presenting at the BIO CEO & Investor Conference at 2:00 p.m. EST on Monday, February 26, 2024.
“We are thrilled to receive a complimentary registration ticket sponsored by New York City Economic Development Corporation (NYCEDC) under Emerging Innovator’s Track,” said Ajay Vishwakarma, DMD, MSc, MBA. “At the BIO CEO & Investor Conference, I’ll will be highlighting Cell BioEngines’ recent developments on its novel stem cell and immune cell therapies for hard-to-treat blood and solid cancers, ongoing pipeline progress, clinical trial updates, and anticipated milestones”, he added.
Details about the presentation are as follows:
Presenter: Dr. Ajay Vishwakarma, Founder and CEO of Cell BioEngines
Date: Monday, February 26, 2024, at 2:00 p.m. EST
Location: Plymouth room, Marriott Marquis, New York, NY
Registration:
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/410c8a90-eda5-4537-bae3-dbb64dd7a610
CONTACT: Contact Mark Joubert., J.D. Chief Legal Officer Cell BioEngines, Inc [email protected]
